$1.10
1.85%
Nasdaq, May 02, 10:00 pm CET
ISIN
IE00BF3W0Q35
Symbol
ITRM
Sector
Industry

Iterum Therapeutics Plc Stock price

$1.10
-0.12 9.84% 1M
-0.22 16.67% 6M
-0.67 37.85% YTD
-0.48 30.38% 1Y
-2.83 72.01% 3Y
-51.93 97.93% 5Y
-191.65 99.43% 10Y
Nasdaq, Closing price Fri, May 02 2025
+0.02 1.85%
ISIN
IE00BF3W0Q35
Symbol
ITRM
Sector
Industry

Key metrics

Market capitalization $38.04m
Enterprise Value $59.51m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-18.70m
Free Cash Flow (TTM) Free Cash Flow $-26.40m
Cash position $24.13m
EPS (TTM) EPS $-1.31
P/E forward negative
P/S forward 4.08
EV/Sales forward 6.38
Short interest 3.67%
Show more

Is Iterum Therapeutics Plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,785 stocks worldwide.

Iterum Therapeutics Plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Iterum Therapeutics Plc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Iterum Therapeutics Plc:

Buy
100%

Financial data from Iterum Therapeutics Plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.54 0.54
69% 69%
-
-0.54 -0.54
69% 69%
-
- Selling and Administrative Expenses 7.70 7.70
34% 34%
-
- Research and Development Expense 10 10
73% 73%
-
-18 -18
60% 60%
-
- Depreciation and Amortization 0.28 0.28
84% 84%
-
EBIT (Operating Income) EBIT -19 -19
61% 61%
-
Net Profit -25 -25
35% 35%
-

In millions USD.

Don't miss a Thing! We will send you all news about Iterum Therapeutics Plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Iterum Therapeutics Plc Stock News

Neutral
GlobeNewsWire
5 days ago
DUBLIN, Ireland and CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today closed the previously announced purchase and sale of an aggregate of 5,555,556 ordinary shares (or ...
Neutral
GlobeNewsWire
6 days ago
DUBLIN, Ireland and CHICAGO, April 29, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has entered into a definitive agreement with a single institutional investor for ...
Neutral
GlobeNewsWire
21 days ago
DUBLIN and CHICAGO, April 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that one poster was presented at the 35th Annual European Congress of Clinical Microbiology and Infectious Disea...
More Iterum Therapeutics Plc News

Company Profile

Iterum Therapeutics Plc is a pharmaceutical company which engages in the development and commercialization of sulopenem to be potentially the first and only oral and intravenous (IV) branded penem available. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. It operates through the Ireland and Unites States geographical segments. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.

Head office Ireland
CEO Corey Fishman
Employees 9
Founded 2015
Website www.iterumtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today